Navigation Links
Intellect Neurosciences Announces Its New CONJUMAB-A Platform Technology for Novel Treatments of Alzheimer's Disease and Other Proteinopathies
Date:10/26/2011

NEW YORK, Oct. 26, 2011 /PRNewswire/ -- Intellect Neurosciences, Inc. (OTCBB: ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases announces today the commencement of the initial development of its new CONJUMAB-A platform technology for a novel class of therapeutics for treatment of Alzheimer's disease and other proteinopathies based on antibody-drug conjugates (ADCs).  Dr. Daniel G. Chain, the Company's Chairman and CEO and inventor of the CONJUMAB-A technology, will provide a brief description of the CONJUMAB-A technology during his presentation at BioInvestor Forum 2011 and in a video interview at the World ADC Summit, both taking place in San Francisco this week.  

The new ADC- based technology has the potential to improve on current methods of passive immunotherapy by increasing clearance of amyloid proteins while delivering potent cytoprotective molecules to sites of damage in the brain and other organs.  CONJUMAB-A is designed to reduce inflammation caused by amyloidosis while avoiding vasogenic edema, a side effect of plaque dissolution that occurs in some patients.   The company's lead CONJUMAB-A candidate is IN-N01-OX2, a non-activating, stabilized IgG4 humanized antibody specific for beta amyloid protein conjugated to melatonin, which is a naturally occurring molecule with potent anti-oxidant and anti-fibrillogenic properties.  

"We believe this exciting new approach may herald a new generation of promising drug candidates for the treatment of currently untreatable life-threatening diseases.  CONJUMAB-A capitalizes on the tremendous advances already made in the area of ADCs for cancer which have generated a plethora of advanced enabling drug conjugation technologies and also uses independent approaches," said Daniel Chain, Ph.D., Chairman and CEO of Intellect Neurosciences and invent
'/>"/>

SOURCE Intellect Neurosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Intellect Neurosciences Issues Letter to Shareholders
2. Intellect Neurosciences CEO to be Featured on Wall Street Reporter
3. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
4. IRIDEX Licenses the Exclusive Rights to Ophthalmology Products and Intellectual Property from Ocunetics, Inc.
5. PILMA Vows to Redouble Support for Increased Protections Against Intellectual Property Theft
6. Dehaier Strengthens Intellectual Property Portfolio
7. NMT Medical, Inc. Adds Intellectual Property to Its Sealed Bid Sale of Friday, June 10, 2011 at Twelve OClock Noon
8. GT Life Sciences Broadens Intellectual Property Portfolio with Issuance of U.S. Patent on Core Computational Systems and Methods for Genomic-based Metabolic Modeling
9. Inovio Pharmaceuticals Market-Leading Intellectual Property Recognized by MDB Capital Award
10. NMT Medical, Inc. Sealed Bid Sale of its Intellectual Property to Take Place Friday, June 10, 2011 at Twelve OClock Noon
11. Software Development Firms New Intellectual Property Group, Blue Horseshoe IP Creates Solutions to Help Customers Optimize Supply Chain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013  NxStage Medical, Inc. (Nasdaq: NXTM ... announced that it has entered into new agreements covering ... to DaVita, the kidney care division of DaVita Healthcare Partners ... For the use of products for home hemodialysis ... has executed a second amended and restated National Service ...
(Date:5/21/2013)... New data released today at the ... that the NeuroStar TMS Therapy System ® ... in patients with Major Depressive Disorder (MDD) during ... through one year of treatment.  At the end ... symptomatic improvement while 41 percent reported complete remission. ...
(Date:5/21/2013)... Quebec , May 21, 2013 ... (NYSE: VRX ) (TSX: ... ten directors nominated at its 2013 ... detailed results of the vote for ... out below:  NameForWithheldRonald H. Farmer235,731,9341,964,748Robert A. ...
Breaking Medicine Technology:NxStage Announces New Agreements with DaVita 2New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System 2New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System 3New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System 4Valeant Pharmaceuticals Announces 2013 Annual Meeting Results 2
... and NEEDHAM, Mass., March 19, 2012  Oridion (SIX ... Index™, one of the Smart Capnography™ family of ... survey conducted at the October 2011 ... (ASA) conference in Chicago. Respondents showed a clear preference ...
... International, Inc. (SGLN.PK) and SurgLine, Inc. ("SurgLine") today announced ... SurgLine have completed the return of over 1,000,000,000 shares of ... up to the previous press release whereby the executives of ... of the restricted shares they were issued of SGLN in ...
Cached Medicine Technology:Survey Shows Anesthesiologists Prefer Capnography for Monitoring Adequacy of Ventilation 2Survey Shows Anesthesiologists Prefer Capnography for Monitoring Adequacy of Ventilation 3Survey Shows Anesthesiologists Prefer Capnography for Monitoring Adequacy of Ventilation 4SurgLine International, Inc. Announces Over 1 Billion Shares Returned to Company 2
(Date:5/21/2013)... from SOURCE XT one of the largest, post-approval ... today at EuroPCR 2013 show good clinical outcomes in ... for all access approaches, valve sizes and delivery systems. ... consecutively enrolled patients (mean age 81.5 years) undergoing TAVI ... in 17 countries between July 2010 and October 2011. ...
(Date:5/21/2013)... 2013, Paris, France: The Orsiro stent, which is ... biodegradable polymer, demonstrated non-inferiority to the Xience Prime ... in-stent late lumen loss at nine months in ... EuroPCR 2013 today. , The BIOFLOW-II substudy used ... to quantitatively assess neointimal hyperplasia and stent apposition ...
(Date:5/21/2013)... AZ (PRWEB) May 21, 2013 ... and inventors who want to develop their ideas ... summer program. , The university is recruiting ... revolutionary new “formation space” that provides early-stage entrepreneurs ... While AREA48 is open to anyone, ASU is ...
(Date:5/21/2013)... According to a May 13, 2013 New ... Botox,” Botox injections have become the most popular ... (Go to goo.gl/8iYbD). Although it is mostly associated with women, ... injection makes facial wrinkles less visible by paralyzing facial muscles. ... three months. This means that people who are conscious about ...
(Date:5/21/2013)... 21, 2013 The federal judge overseeing ... lawsuits in U.S. District Court, Northern District ... a request from Plaintiffs’ Counsel to conduct Ex Parte ... May 17th Order grants that request, and sets forth ... re: Wright Medical Technology, Inc., Conserve Hip Implant Products ...
Breaking Medicine News(10 mins):Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 3Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 4Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3
... completes successful first year , ... Monrovia, Liberia (Vocus) ... increased access to health care for Liberia,s citizens is the availability ... of rebuilding, much of the country,s infrastructure is still in ruins, ...
... of the most debilitating diseases known to man, and new findings ... News Report website. To read the entire report about the ... , ... Boca Raton, Fla. (PRWEB) November 14, 2008 ...
... school, dips in academic performance and classroom participation can ... students to accept newcomers can go a long way ... the conclusion of a new longitudinal study that found ... to declines in academic performance and classroom participation, but ...
... VIRGINIA BEACH, Va., Nov. 13, 2008 James G.,Carlson, Chairman ... statement on America,s "Premature Birth Report Card," which was,released November ... in America deserves a fair chance to grow up in ... clear with its ,Premature,Birth Report Card, that is not the ...
... Marks for its Lack of Overall Plan and,Sense of ... (LCA-CA) issued its 1st annual Report Card on Lung ... to the state for its lack,of progress in reducing ... year than all other major cancer combined., (Logo: ...
... fourth annual EagleBank,Foundation Fight Breast Cancer Golf Classic ... primary beneficiaries: Shady Grove,Adventist Hospital and Suburban Hospital ... Hospital, Providence Hospital and Washington,Hospital Center in Washington, ... Montgomery County. The tournament was held on October ...
Cached Medicine News:Health News:Mercy Ships Ensures That Liberian Technicians "know how to fix it" 2Health News:Mercy Ships Ensures That Liberian Technicians "know how to fix it" 3Health News:Mercy Ships Ensures That Liberian Technicians "know how to fix it" 4Health News:Alzheimer's Disease Cutting Edge Research Announced on Natural Health News Report Website 2Health News:Supportive teachers, peers can ease negative effects of frequent moves in elementary school 2Health News:AMERIGROUP Chairman and CEO Urges Action to Improve Nation's 'Premature Birth Report Card' 2Health News:Lung Cancer Alliance-California Issues Inaugural State-Specific Report Card on Lung Cancer 2Health News:Fourth Annual EagleBank Foundation Fight Breast Cancer Golf Classic Raises Over $100,000 2
Polyester ribbon impregnated with conjugated Protein A - .25 OD per sq. cm....
Polyester ribbons (3) impregnated with different OD values of conjugated Protein G...
Colloidal Gold Sol, 40 nm - 50 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Colloidal Gold Sol, 30 nm 12 - 15 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Medicine Products: